Research LettersImprovement in renal function in hepatorenal syndrome with N-acetylcysteine
References (5)
- et al.
Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club
Hepatology
(1996)
Cited by (155)
Current Medical Treatment for Alcohol-Associated Liver Disease
2022, Journal of Clinical and Experimental HepatologyPredictive factors for 28-day mortality in acute-on-chronic liver failure patients admitted to the intensive care unit
2019, Digestive and Liver DiseaseCitation Excerpt :However, a precise understanding of the importance of different individual components of renal dysfunction in ACLF is still lacking [3]. Despite this, some previous studies exploring the use of anti-inflammatory agents such as N-acetylcysteine [20] and pentoxifylline [21] in patients with hepatorenal syndrome showed a positive impact on renal function. Whether these therapies hold clinical benefit for the renal dysfunction of ACLF remains unclear.
Hepatorenal disorders
2015, ChestHepatorenal syndrome
2014, Nephrologie et TherapeutiqueAcute on chronic liver failure: From pathophysiology to clinical management
2013, Trends in Anaesthesia and Critical CareCitation Excerpt :Moreover, in 30–40% of cirrhotic patients with renal failure bacterial infection, e.g. spontaneous bacterial peritonitis, is the leading cause.77 The role of inflammation and/or oxidative stress in renal failure associated with ACLF is highlighted by the benefit of anti-inflammatory agents such as albumin, pentoxifylline or N-acetylcyteine, which decreased the risk of renal dysfunction in patients with alcoholic hepatitis.80,81 In ACLF, both prerenal and renal causes are involved in the pathogenesis of acute renal failure.